Radiotherapy & Oncology
Volume 94, Issue 2 , Pages 145-150 , February 2010

Validation of functional imaging with pathology for tumor delineation in the prostate

Received 16 October 2009 ,Revised 22 December 2009 ,Accepted 22 December 2009.

References 

  1. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006;24:1990–1996
  2. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  3. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239
  4. Al-Mamgani A, Van Putten WLJ, Heemsbergen WD, et al. Update of dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:980–988
  5. Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53:595–599
  6. Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69:62–69
  7. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90Gy compared to seven field three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:921–929
  8. Van Lin ENJT, Fütterer JJ, Heijmink SWTPJ, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65:291–303
  9. Singh AK, Guion P, Sears-Crouse N, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95Gray with IMRT: early results of a phase I NCI study. Radiat Oncol. 2007;2:36
  10. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging. 2006;23:130–134
  11. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 T. Invest Radiol. 2006;41:185–188
  12. Kumar V, Jagannathan NR, Kumar R, et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed. 2007;20:505–511
  13. Van Dorsten FA, van der Graaf M, Engelbrecht MRW, et al. Combined quantitative dynamic contrast-enhanced MR imaging an 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004;20:279–287
  14. Franiel T, Lüdemann L, Rudolph B, et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol. 2008;43:481–487
  15. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis – correlation with biopsy and histopathology. J Magn Reson Imaging. 2006;24:108–113
  16. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3T: a study of pharmacokinetic parameters. Am J Roentgenol. 2007;189:849
  17. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging – clinicopathologic study. Radiology. 1999;213:473–480
  18. Fütterer JJ, Heijmink SWTPJ, Scheenen TWJ, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–458
  19. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004;20:654–661
  20. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging. 2005;21:258–262
  21. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol. 2007;61:297–302
  22. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol. 2007;189:323–328
  23. van Vulpen M, van den Berg CAT, Moman MR, van der Heide UA. Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. Radiother Oncol. 2009;93:180–184
  24. Franiel T, Lüdemann L, Taupitz M, Bömer D, Beyersdorff DD. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Radiother Oncol. 2009;93:241–245
  25. Kershaw LE, Logue JP, Hutchinson CE, Clarke NW, Buckley DL. Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging. Radiother Oncol. 2008;88:127–134
  26. Park H, Piert MR, Khan A, et al. Registration methodology for histological sections and in vivo imaging of human prostate. Acta Radiol. 2008;15:1027–1039
  27. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–232
  28. Murase K. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med. 2004;51:858–862
  29. Klein S, Staring M, Murphy K, Viergever MA, Pluim JPW. Elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med Imaging. 2010;29:196–205
  30. Van der Put RW, Raaymakers BW, Kerkhof EM, Van Vulpen M, Lagendijk JJW. A novel method for comparing 3D target volume delineations in radiotherapy. Phys Med Biol. 2008;53:2149–2159
  31. Langer DL, Van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2 – sparse versus dense cancers. Radiology. 2008;249:900–908
  32. Klein S, van der Heide UA, Lips IM, van Vulpen M, Staring M, Pluim JPW. Automatic segmentation of the prostate in 3D MR images by atlas matching using localized mutual information. Med Phys. 2008;35:1407–1417
  33. Van der Heide UA, Kotte ANTJ, Dehnad H, Hofman P, Lagendijk JJW, Van Vulpen M. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol. 2007;82:38–45
  34. Goitein M, Niemierko A. Intensity modulated therapy and inhomogeneous dose to the tumor: a note of caution. Int J Radiat Oncol Biol Phys. 1996;36:519–522

PII: S0167-8140(10)00011-3

doi: 10.1016/j.radonc.2009.12.034

Radiotherapy & Oncology
Volume 94, Issue 2 , Pages 145-150 , February 2010

Article Tools

* Image Usage & Resolution